Evidence map›Paper›PMID 36780234›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2023

Application of Novel Breast Biospecimen Cell-Type Adjustment Identifies Shared DNA Methylation Alterations in Breast Tissue and Milk with Breast Cancer-Risk Factors.

Meghan E Muse, Connolly D Carroll, Lucas A Salas, Margaret R Karagas, Brock C Christensen

Open access · hybridAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Meghan E MuseDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.ORCID 0000-0002-4775-2133
Connolly D CarrollDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.ORCID 0000-0001-7075-4033
Lucas A SalasDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.ORCID 0000-0002-2279-4097
Margaret R KaragasDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.ORCID 0000-0002-6398-7362
Brock C ChristensenDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.ORCID 0000-0003-3022-426X
Dartmouth College · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
A prospective study of critical environmental exposures in formative early life that impact lifelong health in rural US children: the New Hampshire Birth Cohort StudyUH3OD023275 · OD · DARTMOUTH COLLEGE · PI MARGARET Rita KARAGAS, Juliette Madan · 2018 to 2026
$44.3M
Relation Between In-utero Vitamin D and Immune Function in Early Childhood P20GM104416 · NIGMS · DARTMOUTH COLLEGE · PI CHRISTENSEN, BROCK CLARKE · 2013 to 2022
$23.7M
Project 3: Placental Biomarkers of Exposure and Outcome (Marsit)P01ES022832 · NIEHS · DARTMOUTH COLLEGE · PI MURRAY, CAROLYN J · 2013 to 2018
$4.7M
DNA-based Immune Phenotyping in HNSCC for Biomarkers of Response to ImmunotherapyR01CA253976 · NCI · BROWN UNIVERSITY · PI CHRISTENSEN, BROCK C, KELSEY, KARL TIMOTHY · 2021 to 2025
$3.3M
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomesR01CA216265 · NCI · DARTMOUTH COLLEGE · PI CHRISTENSEN, BROCK CLARKE · 2017 to 2021
$2.9M
Training Program for Quantitative Population Sciences in CancerT32CA134286 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA, TOSTESON, TOR D · 2020 to 2024
$1.5M
NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA216265NCI NIH HHS R01 CA253976NCI NIH HHS T32 CA134286NIEHS NIH HHS P01 ES022832NIGMS NIH HHS P20 GM104416NIH HHS UH3 OD023275Wellcome Trust
6 · The paper itself

Abstract

backgroundDNA methylation patterning is cell-type-specific and altered DNA methylation is well established to occur early in breast carcinogenesis, affecting non-cancerous, histopathologically normal breast tissue. Previous work assessing risk factor-associated alterations to DNA methylation in breast tissue has been limited, with even less published research in breast milk, a noninvasively obtained biospecimen containing sloughed mammary epithelial cells that may identify early alterations indicative of cancer risk.

methodsHere, we present a novel library for the estimation of the cellular composition of breast tissue and milk and subsequent assessment of cell-type-independent alterations to DNA methylation associated with established breast cancer-risk factors in solid breast tissue (n = 95) and breast milk (n = 48) samples using genome-scale DNA methylation measures from the Illumina HumanMethylation450 array.

resultsWe identified 772 hypermethylated CpGs (P < 0.01) associated with age consistent between breast tissue and breast milk samples. Age-associated hypermethylated CpG loci were significantly enriched for CpG island shore regions known to be important for regulating gene expression. Among the overlapping hypermethylated loci mapping to genes, a differentially methylated region was identified in the promoter region of SFRP2, a gene observed to undergo promoter hypermethylation in breast cancer.

conclusionsOur findings suggest the potential to identify epigenetic biomarkers of breast cancer risk in noninvasively obtained, tissue-specific breast milk specimens. IMPACT: This work demonstrates the potential of using breast milk as a noninvasive biomarker of breast cancer risk, improving our ability to detect early-stage disease and lowering the overall disease burden.

Indexed as

Breast NeoplasmsDNA MethylationAnimalsCpG IslandsEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansMilkRisk Factors

Identifiers

PMID36780234
PMCPMC10068446
OpenAlexW4320486105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.